Healthcare resource utilisation and direct medical cost for individuals with 5q spinal muscular atrophy in Sweden

Thomas Sejersen, Sophie Graham, Anne‐Berit Ekström, Anna‐Karin Kroksmark, Marta Kwiatkowska, Michael L. Ganz, Nahila Justo, Karl Gertow, Alex SimpsonThe European Journal of Health Economics 2024 · DOI

Abstract: The economic burden attributable to spinal muscular atrophy (SMA) is significant. This study quantifies the healthcare resource utilisation (HCRU) and direct medical costs associated with different types of SMA in Sweden, providing a critical baseline for evaluating the cost-effectiveness of new disease-modifying therapies.

Introduction

Spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disorder caused by a genetic defect. Historically, treatment was limited to symptom management, but the recent introduction of disease-modifying therapies (DMTs) like nusinersen, risdiplam, and onasemnogene abeparvovec has revolutionized care.

However, these new treatments are among the most expensive drugs in the world. To make informed reimbursement and "value-based" healthcare decisions, policymakers need to know the "baseline" cost of the disease—the actual economic burden of treating SMA without or alongside these new interventions. Prior to this study, European data was often limited to small-scale surveys or interviews, which lacked the breadth and precision of national registry data.

Methodology

The researchers conducted a population-based matched-reference cohort study using data from six different Swedish national registries spanning 2007 to 2018. The cohort included 290 SMA patients, each matched to four individuals from the general population (1,160 total) based on age, sex, and county. Patients were classified into four groups: Type 1 (most severe), Type 2, Type 3, and Unspecified Adult Onset (UAO).

To model a "lifetime" trajectory of costs and resource use despite the rarity of the condition, the authors employed "synthetic cohorts." This statistical technique aggregates data from different individuals at various stages of the disease. Direct medical costs were estimated by multiplying HCRU (including inpatient stays and specialist outpatient visits) by unit costs provided by the Swedish National Board of Health and Welfare.

Key Results

The study revealed a staggering disparity in healthcare costs. A Type 1 SMA patient averages approximately €114,185 in annual medical costs, compared to just €804 for a matched peer in the general population. Across all SMA types, costs were not linear; they peaked significantly 2 to 3 years after the first diagnosis, likely reflecting the intensive period of establishing care, surgeries, and initial complications.

The risk ratio for overnight hospital stays was 29.2 for Type 1 and 23.3 for Type 2, highlighting that the primary economic driver is acute hospital care rather than just outpatient management. Medication trends also showed a high respiratory burden, with nearly 90% of Type 2 patients requiring systemic antibacterials.

Healthcare resource utilization (HCRU) for different SMA types, illustrating inpatient day cases and prescribed medications.

While UAO SMA is often considered "mild," these patients showed a different type of burden—specifically higher rates of anxiety, depression, and opioid use compared to their peers. Since the approval of nusinersen in 2017, about half of the Type 2 and one-third of the Type 1 patients in the study had started on this DMT.

Discussion and Conclusion

There are some limitations to this study. Sweden lacks a national registry for primary care (GP visits), so the true HCRU is likely even higher than reported. Additionally, because nusinersen was only introduced toward the end of the study period, its full long-term impact on costs and HCRU isn't fully realized in this data.

This study provides a comprehensive look at the economic and healthcare burden of 5q SMA in Sweden. As newer gene therapies become more common, this study provides a critical baseline. Future research must evaluate if the high upfront cost of these drugs is offset by a reduction in the massive annual hospital costs identified here.

Summary updated

Abstract

The economic burden attributable to SMA is significant. Further research is needed to understand the burden in other European countries and the impact of new treatments.
BibTeX
@article{sejersen2024healthcare,
  author = {Thomas Sejersen and Sophie Graham and Anne‐Berit Ekström and Anna‐Karin Kroksmark and Marta Kwiatkowska and Michael L. Ganz and Nahila Justo and Karl Gertow and Alex Simpson},
  title = {{Healthcare resource utilisation and direct medical cost for individuals with 5q spinal muscular atrophy in Sweden}},
  journal = {The European Journal of Health Economics},
  year = {2024},
  doi = {10.1007/s10198-024-01678-y},
}
Figure